Lauren Sabella Joins Mannkind as Executive Vice President

[porkini]

investors.mannkindcorp.com/node/18846/pdf

investors.mannkindcorp.com/news-releases/news-release-details/lauren-sabella-joins-mannkind-executive-vice-president-chief

Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer
March 27, 2023
DANBURY, Conn., March 27, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and
commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Lauren Sabella has
joined the company as Executive Vice President, Chief Operating Officer, effective today. Sabella will report directly to Michael Castagna, PharmD,
Chief Executive Officer, and serve on the company’s executive leadership team.
“Lauren is an inspirational leader, and we are delighted to welcome her to MannKind at a pivotal time,” said Dr. Castagna. “Lauren will be leading all
our critical functions that operate in Danbury, focused on growing our endocrine business and preparing to launch our emerging pipeline in the orphan
lung area.”
Sabella brings deep commercial, respiratory, and operational experience to MannKind with a career that has spanned small-cap to large-cap
pharmaceutical companies. Prior to MannKind, she was at Acorda Therapeutics for 12 years. Her last role was Chief Operating Officer, where she had
responsibility for overall business operations including quality, medical affairs, regulatory, technical operations, information technology, project
management, and pharmaceutical development departments as well as the strategic planning function for the organization. Prior to that role, Sabella
was Acorda’s Chief Commercial Officer and launched their flagship product Ampyra ® for multiple sclerosis whose peak sales exceeded half a billion
dollars. Earlier in her career, she was Vice President of Commercial Development at Altus Pharmaceuticals with responsibility for all aspects of
commercialization. Sabella also spent 18 years at Boehringer Ingelheim Pharmaceuticals in positions of increasing responsibility, which included over
10 years of marketing experience and an impressive accomplishment of two product launches that surpassed $1 billion in sales. A graduate of Hofstra
University, Sabella will be based in Danbury.
“I am honored and excited to be joining MannKind as it continues to scale and execute its plan to help people living with endocrine and orphan lung
diseases,” said Sabella. “I am energized to work with this innovative team as we drive operational excellence in an action-driven environment.”
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to
address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary
arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and
inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic
circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.


The "About Team" page must be undergoing an update, cannot reach it currently (mannkindcorp.com/about/team/)

[tingtongtung]

From, ACOR: 55 cents

What happened to AMGN people that were supposed to come here? /s

[longliner]

Welcome aboard Lauren! It's great to have your energy directly in Danbury!  Where the action is!


Q the bashing on all platforms, she hasn't even been properly introduced. The same thing happened with Desisto and MC.......I guess it's a how the trash make their living.

[sla55]

Form 8-k
investors.mannkindcorp.com/static-files/e85680a6-532c-4ae5-b239-4a8087c489b7


On March 21, 2023, Lauren M. Sabella was appointed by the board of directors of MannKind Corporation (the “Company”) as Executive Vice President, Chief Operating Officer of the Company, with such appointment to be effective on March 27, 2023.
Prior to her appointment as Executive Vice President, Chief Operating Officer, Ms. Sabella, age 62, served as Principal at LS Consulting Group, a strategic advisory group providing consulting services to pharmaceutical and emerging biotech companies, from September 2022 until March 2023. From September 2021 until September 2022, Ms. Sabella served as Chief Operating Officer at Acorda Therapeutics, Inc. (“Acorda”). Ms. Sabella was previously Acorda’s Chief Commercial Officer from February 2015 to September 2021. Before that, from January 2010 to February 2015, she was Acorda’s Executive Vice President, Commercial Development. Prior to that, Ms. Sabella was the Founder and Principal of Tugboat Consulting Group, an independent consulting practice assisting companies in the commercialization process. Ms. Sabella also served as Corporate Officer and Vice President of Commercial Development at Altus Pharmaceuticals Inc. (“Altus”) from May 2006 to September 2008, with responsibility for all aspects of commercialization. Prior to joining Altus, Ms. Sabella was employed by Boehringer Ingelheim Pharmaceuticals for 18 years in positions of increasing responsibility, which included over ten years of marketing experience during which she led several product launches including Mobic, an NSAID that became a $1 billion brand. In her last role, she served as Vice President of Sales, Eastern Zone, where she led the sales launch of Spiriva and ran both Primary Care and Specialty Divisions, including Neurology, Urology and Cardio/Pulmonary. Ms. Sabella holds a B.B.A. from Hofstra University.
In connection with her appointment, the Company entered into an employment offer letter with Ms. Sabella that governs the current terms of her employment with the Company. The employment offer letter provides that Ms. Sabella will receive an annual base salary of $440,000 and will be eligible to receive an annual performance bonus with a target bonus percentage equal to 50% of her base salary. The employment offer letter also provides that the Company will grant Ms. Sabella an equity award of 210,000 restricted stock units, which will vest 25% on each of the first four anniversaries of the grant date, subject to continuing service. In addition, pursuant to a Change of Control Agreement in substantially the form filed with the Securities and Exchange Commission (“SEC”) on April 7, 2017 as Exhibit 99.1 to the Company’s Current Report on Form 8-K, if Ms. Sabella’s employment is subject to an involuntary termination within two years following a change in control, she will be entitled to receive continued payment of base salary for 18 months, payment of her group health insurance premiums for up to 18 months, a prorated annual performance bonus and full accelerated vesting of any unvested equity awards. Ms. Sabella may also be entitled to receive tax gross up payments in the event any payments made in connection with a change in control are subject to the excise taxes imposed by Sections 280G and 4999 of the Internal Revenue Code.
Ms. Sabella will also enter into an indemnity agreement with the Company in the form previously filed with the SEC as Exhibit 10.1 to the Company’s Registration Statement on Form S-1, originally filed with the SEC on April 30, 2004, as amended.
There are no family relationships between Ms. Sabella and any of the Company’s current or former directors or executive officers. Ms. Sabella is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act of 1933, as amended.
The foregoing summary of the employment offer letter with Ms. Sabella is qualified in its entirety by reference to the full text of the agreement, a copy of which is filed with this Current Report on Form 8-K as Exhibit 10.1.
Item 7.01 Regulation FD Disclosure.
On March 27, 2023, the Company issued a press release announcing Ms. Sabella’s appointment as discussed in Item 5.02 herein. A copy of the press release is attached as Exhibit 99.1 hereto and is hereby incorporated by reference in its entirety. The information in this Item 7.01 and the attached Exhibit 99.1 to this Current Report on Form 8-K is being furnished (not filed) pursuant to Item 7.01 of Form 8-K.

[lennymnkd]

Sabella also spent 18 years at Boehringer Ingelheim Pharmaceuticals in positions of increasing responsibility, which included over 10 years of marketing experience and an impressive accomplishment of two product launches that surpassed $1 billion in sales. A graduate of Hofstra University, Sabella will be based in Danbury.

All I see 😳 !

[lennymnkd]

www.acorda.com/products/products/inbrija

Some background 🤔inhalation ?

[longliner]

Plus
whiskyqueen
12:47 PM
$MNKD Here we go… 🍿 to all the bashers spinning how negative this new hire is for the company. 18 years with Boehringer…The company who currently markets clofazamine.. 🧐

[uvula]

Is this a new position or replacing someone?

[awesomo]

Lauren Sabella LinkedIn

According to her LinkedIn, she was at Boehringer for 6 years (2000-2006) and served as a VP of Sales for 4 years.

More recently and at a similar C-suite level, she was Chief Commercial Officer of Acorda Therapeutics for 11 years from 2010-2021, and Chief Operating Officer for 1 year (2021-2022).

The share price of Acorda in 2010 (when she started) was around $170, it is now 57 cents.

[uvula]

Any reverse splits?

[lennymnkd]

Acorda’s lead multiple sclerosis (MS) drug Ampyra is facing generic competition in the United States after it lost exclusivity in September 2018 including Mylan's MYL authorized generic version. During the first nine months of 2019, sales of Ampyra have tanked 68.7% year over year due to generic launches.

She is not Al mann ! Only as good as what she had to work with .

[awesomo]

Mar 27, 2023 18:42:06 GMT -5 uvula said:

Any reverse splits?

Yep, in Jan 2021.

[caesar]

Mar 27, 2023 18:33:11 GMT -5 awesomo said:

Lauren Sabella LinkedIn

According to her LinkedIn, she was at Boehringer for 6 years (2000-2006) and served as a VP of Sales for 4 years.

More recently and at a similar C-suite level, she was Chief Commercial Officer of Acorda Therapeutics for 11 years from 2010-2021, and Chief Operating Officer for 1 year (2021-2022).

The share price of Acorda in 2010 (when she started) was around $170, it is now 57 cents.

Never know - might be a company that Mannkind is considering purchasing.

With only 24 million shares outstanding, and @ 0.57/share price it might be worth purchasing.  Acorda also has an innovative pulmonary delivery system called ARCUS®, a technology platform designed to deliver medication through inhalation.
 
NOTE:

If at any time before June 20, 2023 the bid price of Acorda’s stock closes at or above $1 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Nasdaq Listing Rules. In the event that the Company cannot regain compliance organically during the extension period, the Company has committed to effecting a reverse stock split, which was authorized by shareholders in November 2022.

[Deleted]

Mar 27, 2023 18:33:11 GMT -5 awesomo said:

Lauren Sabella LinkedIn

According to her LinkedIn, she was at Boehringer for 6 years (2000-2006) and served as a VP of Sales for 4 years.

More recently and at a similar C-suite level, she was Chief Commercial Officer of Acorda Therapeutics for 11 years from 2010-2021, and Chief Operating Officer for 1 year (2021-2022).

The share price of Acorda in 2010 (when she started) was around $170, it is now 57 cents.

You're gonna catch hell for this!

[lennymnkd]

Mar 27, 2023 19:01:18 GMT -5 caesar said:

Mar 27, 2023 18:33:11 GMT -5 awesomo said:

Lauren Sabella LinkedIn

According to her LinkedIn, she was at Boehringer for 6 years (2000-2006) and served as a VP of Sales for 4 years.

More recently and at a similar C-suite level, she was Chief Commercial Officer of Acorda Therapeutics for 11 years from 2010-2021, and Chief Operating Officer for 1 year (2021-2022).

The share price of Acorda in 2010 (when she started) was around $170, it is now 57 cents.

Never know - might be a company that Mannkind is considering purchasing.

With only 24 million shares outstanding, and @ 0.57/share price it might be worth purchasing.  Acorda also has an innovative pulmonary delivery system called ARCUS®, a technology platform designed to deliver medication through inhalation.
 
NOTE:

If at any time before June 20, 2023 the bid price of Acorda’s stock closes at or above $1 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Nasdaq Listing Rules. In the event that the Company cannot regain compliance organically during the extension period, the Company has committed to effecting a reverse stock split, which was authorized by shareholders in November 2022.